Leukotriene E4

A biologically active principle of SRS-A that is formed from LEUKOTRIENE D4 via a peptidase reaction that removes the glycine residue. The biological actions of LTE4 are similar to LTC4 and LTD4. (From Dictionary of Prostaglandins and Related Compounds, 1990)

Also Known As:

Networked: 414 relevant articles (15 outcomes, 49 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rabinovitch, Nathan: 10 articles (01/2020 - 05/2006)
2.	Akiyama, K: 8 articles (01/2009 - 11/2001)
3.	Mita, H: 8 articles (01/2009 - 11/2001)
4.	Taniguchi, M: 8 articles (01/2009 - 11/2001)
5.	Kanaoka, Yoshihide: 7 articles (01/2021 - 08/2007)
6.	Taniguchi, Masami: 7 articles (01/2020 - 02/2004)
7.	Sanak, Marek: 6 articles (01/2021 - 01/2012)
8.	Higashi, Noritaka: 6 articles (12/2016 - 02/2004)
9.	Higashi, N: 6 articles (01/2009 - 06/2003)
10.	Boyce, Joshua A: 5 articles (01/2019 - 10/2009)

Related Diseases

1.	Asthma (Bronchial Asthma) 12/01/1997 - "In atopic asthmatics, urinary excretion of LTE4 and 11DTXB2 was significantly higher on admission with an asthma attack, and returned to control levels when the patients were in the improved state (179+/-29 to 65+/-16 ng/day in LTE4, 1,085+/-250 to 440+/-90 ng/day in 11DTXB2). " 11/01/1995 - "Although the magnitude of variation in LTE4 excretion within a day was significantly greater in patients with asthma than in normal subjects (p < 0.05), we could not identify any specific diurnal variation pattern in either the normal or the asthma group. " 01/01/2014 - "The goal of this study was to evaluate the impact of urinary leukotriene E4 (ULTE4) in asthmatic children during acute asthma exacerbation. " 01/01/2014 - "Study of urinary leukotriene E4 levels in children with acute asthma." 11/01/2009 - "This study aimed to evaluate the clinical significance of urinary leukotriene E(4) (LTE(4)) in childhood asthma. "
2.	Inflammation (Inflammations) 12/01/2019 - "2,3-d-TXB2 and LTE4, which are linked to platelet activation and inflammation, represent BoPH in short-term tobacco product-switching studies. " 01/01/2021 - "Persistent Eosinophilic Inflammation in Adult Asthmatics with High Serum and Urine Levels of Leukotriene E4." 01/01/2021 - "These findings suggest that higher levels of TGF-β1 in AERD patients may contribute to LTE4 production via enhancing LTC4S expression which induces eosinophil degranulation, accelerating airway inflammation." 03/01/2012 - "Furthermore, urinary LTE4 concentrations are of potential use as a marker of inflammation in dogs with CCE." 07/01/1991 - "In certain situations, urinary LTE4 levels may be useful as a marker of the degree of inflammation."
3.	Airway Obstruction (Choking) 09/01/2006 - "Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction." 07/01/1992 - "Recovery of leukotriene E4 from the urine of patients with airway obstruction." 05/01/1995 - "In addition, a post-challenge increase in urinary LTE4 levels was detected in association with allergen-induced airway obstruction in atopic asthmatics. " 09/01/1989 - "Thus, although LTD4 and LTE4 are though to act on the same or similar receptors, the pattern of pharmacologic reversal at comparable levels of airway obstruction differs for these two agonists." 01/01/2004 - "Montelukast produced improvement in airway obstruction, daily symptom scores, total daily as-needed beta-agonist use, nocturnal awakenings, percentage of days and percentage of patients with asthma exacerbations, and urinary leukotriene E4 levels. "
4.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2012 - "We also did not find any difference between LTE4 level in urine and 9α11βPGF(2) in blood and urine between exacerbated and stable COPD. " 04/01/2007 - "Leukotriene E(4) (LTE(4)) is implicated in asthma pathophysiology and possibly in chronic obstructive pulmonary disease (COPD) as one of the causes of persistent bronchoconstriction and mucus hypersecretion. " 04/01/2007 - "Leukotriene E(4) in urine in patients with asthma and COPD--the effect of smoking habit." 03/01/1997 - "Plasma levels of leukotriene E4 during clinical course of chronic obstructive pulmonary disease." 03/01/1997 - "The mean leukotriene E4 level in patients with COPD during remission, during acute exacerbation before and after prednisolone treatment were 16.8[4.02], 41.7[21.9], and 19.5[3.78] pg/ml (mean[SD]), respectively. "
5.	Pulmonary Hypertension 01/01/1997 - "These data suggest that neither the surgical repair during cardiopulmonary bypass nor the pulmonary hypertension appeared to modify the leukotriene E4 blood levels in the small number of patients studied." 01/01/2000 - "Since urinary LTE4 excretion is increased in various cardiovascular diseases, including arterial pulmonary hypertension or cardiac ischaemia, the study of the effects of leukotrienes on human vascular preparations is of interest. " 09/01/1992 - "We conclude that 1) the extended pulmonary hypertension induced by PAF was caused mainly by prolonged activation of 5-lipoxygenase with LTC4 production, 2) the relative overall lung clearance of LTB4, LTD4, and LTE4 was slower than that of LTC4, and 3) LTB4, LTD4, and LTE4 had no appreciable pressor effect."

Related Drugs and Biologics

1.	Leukotriene D4
2.	Leukotriene B4
3.	Leukotriene C4
4.	montelukast (Singulair)
5.	Aspirin (Acetylsalicylic Acid)
6.	cysteinyl-leukotriene
7.	Eosinophil-Derived Neurotoxin
8.	Thromboxane B2
9.	Carnitine (L-Carnitine)
10.	Biomarkers (Surrogate Marker)

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Oral Administration
5.	Tourniquets